Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 June 2021 | Story Leonie Bolleurs | Photo Supplied
Zurika Murray says the study of Behavioural Genetics at the UFS focuses on human behaviour, specifically neurotransmitter systems, such as serotonin that may contribute to specific behavioural patterns.
Zurika Murray says the study of Behavioural Genetics at the UFS focuses on human behaviour, specifically neurotransmitter systems, such as serotonin that may contribute to specific behavioural patterns.

Hi. I am John. I have anger issues.

Just like John, there are thousands of South Africans with anger issues, often leading to violent crimes such as the more than 21 000 murder cases and 165 000 plus assault cases reported in 2020, according to a study by the South African Police Service and Statistics South Africa.

Aggression can be a great threat to society when it leads to violence. However, it can also be an absolute necessity when it leads to perseverance and a drive towards success and survival. This is according to Zurika Murray, a lecturer in the Department of Genetics at the University of the Free State (UFS), who is doing research on behavioural genetics.

 

Behavioural genetics

She explains behavioural genetics as a study of genetic variation contributing to how an organism interacts with and within its environment. “At the UFS, we focus on human behaviour, and specifically neurotransmitter systems, such as serotonin that may contribute to specific behavioural patterns.”

When one has the right amount of serotonin in your body, it is easier to have stable moods and a sense of well-being.

She says the neurotransmitter (which plays a role in, among others, emotional regulation) acts as a mediator, relaying messages and influencing response to environmental stimuli.  “This system is very adaptable, facilitating our functioning in an ever-changing emotional environment; but when dysfunctional, it can cause quite a number of abnormalities, from anxiety and depression to dysfunctional impulse control and violence. When some individuals are exposed to adverse developmental environments such as abuse and neglect, they can develop aggression and violence.”

“One of our current projects looks specifically at male juvenile delinquency and monoamine neurotransmitter systems (such as serotonin) that may contribute to specific characteristics (such as impulsivity) of delinquency.”

According to Murray, their research is also looking at the genetic variation within specific neurotransmitter genes to see if they could find similarities among individuals with similar developmental backgrounds.  “This neurotransmitter system additionally responds relatively well to physical activity as a management strategy for aggression in some individuals. We are looking at variations in this system that might explain this,” says Murray.

 

Genetic counselling

Apart from the genetic contribution, we also know that the developmental environment plays a very important role. Many people observe anger while growing up – it was thus part of their developmental environment. For them, it is appropriate behaviour in specific situations.

To understand this contribution from the developmental environment, a background in psychology is necessary.  The undergraduate degree in Behavioural Genetics at the UFS has Genetics and Psychology as majors, and this is where the link to genetic counselling comes in.

Murray explains that genetic counselling is a field in medical sciences focusing on helping patients affected by medical conditions to understand the underlying genetics.  For individuals with a family history of genetic conditions (such as specific cancers) or pregnant mothers with foetuses affected by genetic abnormalities (such as Down syndrome), the services of a genetic counsellor are invaluable.  A genetic counsellor will help these individuals understand the cause of the disorder, how it was diagnosed, what the symptoms are, what the progression will look like, if any treatment is available, and what the possible options are (if any) for alternatives.

Genetic counsellors need a strong background in both Genetics and Psychology. To become a registered genetic counsellor, a student completes a BSc degree in Biological Sciences (Behavioural Genetics at the UFS would be ideal).  Thereafter an honours degree in either Genetics or Psychology (though Genetics is preferable).  The student can then apply at either the University of the Witwatersrand or the University of Cape Town for a master’s degree in Genetic Counselling.  This entails two years of study, followed by two years of practical internship. Only after this you will be able to register with the Health Professions Council of South Africa (HPCSA) as a genetic counsellor.

Students studying Behavioural Genetics at the UFS are off to a great start. Murray’s teaching philosophy is to always strive to deliver students who are better than she is. “I can only really do this by sharing my passion for my research. I hope to inspire my students to also always be hungrily curious, to always question, and to find the joy in knowledge and learning.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept